Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Darya-Varia Laboratoria Tbk's quarterly Total Liabilities
increased
from Sep. 2025 (Rp852,958.99 Mil) to Dec. 2025 (Rp870,439.59 Mil) and
increased
from Dec. 2025 (Rp870,439.59 Mil) to Mar. 2026 (Rp982,053.53 Mil).
PT Darya-Varia Laboratoria Tbk's annual Total Liabilities
increased
from Dec. 2023 (Rp637,739.73 Mil) to Dec. 2024 (Rp712,565.63 Mil) and
increased
from Dec. 2024 (Rp712,565.63 Mil) to Dec. 2025 (Rp870,439.59 Mil).
PT Darya-Varia Laboratoria Tbk Total Liabilities Related Terms
PT Darya-Varia Laboratoria Tbk Total Liabilities Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Darya-Varia Laboratoria Tbk Total Liabilities Chart
PT Darya-Varia Laboratoria Tbk Total Liabilities Calculation
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of Rp982,054 Mil mean?
PT Darya-Varia Laboratoria Tbk (ISX:DVLA) has a Total Liabilities of Rp982,054 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for PT Darya-Varia Laboratoria Tbk and its competitors.
Is PT Darya-Varia Laboratoria Tbk's Total Liabilities too high?
PT Darya-Varia Laboratoria Tbk's current Total Liabilities is Rp982,054 Mil. Overall, PT Darya-Varia Laboratoria Tbk has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Darya-Varia Laboratoria Tbk's Total Liabilities compare to ZTS and UTHR?
PT Darya-Varia Laboratoria Tbk's Total Liabilities of Rp982,054 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for PT Darya-Varia Laboratoria Tbk and its competitors. PT Darya-Varia Laboratoria Tbk's current Total Liabilities is Rp982,054 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Darya-Varia Laboratoria Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Darya-Varia Laboratoria Tbk (ISX:DVLA) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp1,845.60, compared to a current price of Rp1,560.00 — trading 15.5% below its estimated fair value. The current Total Liabilities is Rp982,054 Mil. PT Darya-Varia Laboratoria Tbk's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For PT Darya-Varia Laboratoria Tbk (ISX:DVLA), the current Total Liabilities is Rp982,054 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Darya-Varia Laboratoria Tbk (ISX:DVLA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Darya-Varia Laboratoria Tbk stock appears to be undervalued.
The current stock price of Rp1,560.00 is trading 15.5% below its estimated GF Value™ of Rp1,845.60.
GuruFocus considers PT Darya-Varia Laboratoria Tbk to be Modestly Undervalued.
Key valuation signals for ISX:DVLA:
Total Liabilities: Rp982,054 Mil
GF Value™: Rp1,845.60 vs. price of Rp1,560.00 (15.5% below fair value)
No single metric tells the full story. See the ISX:DVLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Darya-Varia Laboratoria Tbk Business Description
PT Darya-Varia Laboratoria Tbk (Darya-Varia) is operating in the pharmaceutical industry. It is engaged in the manufacture and trade of pharmaceutical products, human, traditional medicines, pharmaceutical materials, raw materials for traditional medicines, inorganic base chemicals, organic base chemicals, equipment for surgery, medical and dental care, and equipment, orthopedic equipment, prosthetic, eyeglasses, laboratory and health equipment from glass, cosmetics, wholesaler of pharmaceutical, traditional medicine, chemical base materials, laboratory testing services, periodic inspection services, and many more activities. Its business segments include: prescription drugs; consumer health products, which derives key revenue; export and toll manufacturing services; and services.
73GF Score
Get the complete analysis for ISX:DVLA
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:DVLA has been successfully added to your 
